| アブストラクト | This cohort study assessed the pancreatic safety of vildagliptin versus other noninsulin antidiabetic drugs (NIADs) based on data from five European electronic health care databases. Patients with type 2 diabetes aged >/=18 years on NIAD treatment were enrolled. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated separately for acute pancreatitis and pancreatic cancer for vildagliptin (+/- other NIADs) compared with other NIADs using negative binomial regression. Approximately 2.8% of the enrolled patients (n = 738 054) used vildagliptin during the study, with an average follow-up time of 1.4 years. For acute pancreatitis, adjusted IRRs ranged between 0.89 andt 2.58 with all corresponding 95% CIs crossing 1. For pancreatic cancer adjusted IRRs ranged from 0.56 to 3.64, with the lower limit of 95% CIs >1 in some analyses. Post hoc sensitivity analyses taking latency time into account markedly lowered the risk estimates with corresponding 95% CIs crossing 1. Overall, the results do not suggest an increased pancreatitis risk with vildagliptin, while the observation for pancreatic cancer have to be interpreted carefully as this study was not designed to assess pancreatic cancer and rather be explained by certain underlying limitations including latency -time, chance findings and/or bias and confounding. |
|---|
| ジャーナル名 | Endocrinology, diabetes & metabolism |
|---|
| Pubmed追加日 | 2019/4/23 |
|---|
| 投稿者 | Williams, Rachael; Kothny, Wolfgang; Serban, Carmen; Lopez-Leon, Sandra; Schlienger, Raymond |
|---|
| 組織名 | Clinical Practice Research Datalink London UK.;Novartis Pharma AG Basel Switzerland.;Novartis Pharmaceuticals Corporation East Hanover New Jersey. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31008361/ |
|---|
